-
December 2011
Sigmapharm successfully completes an FDA inspection focused on its current GMP status and a Pre-Approval-Inspection related to its ANDA No. 202819.
-
November 2011
Sigmapharm launches, through Rising Pharmaceuticals, Inc., its 5th generic product, Flucytosine Capsules, USP 250 mg and 500 mg, which is the first-and-only approved generic equivalent to ANCOBON® Capsules.
-
June 2011
Sigmapharm receives FDA approval for generic Flucytosine Capsules, USP 250 mg and 500 mg, based on its ANDA No. 201566.
-
May 2011
Sigmapharm successfully completes an FDA inspection focused on its current GMP status and a Pre-Approval-Inspection related to its ANDA No. 202051.
-
April 2011
Sigmapharm launches, through Rising Pharmaceuticals, Inc., its 4th generic product, Disulfiram Tablets, USP 250 mg, which is the first-and-only approved generic equivalent to ANTABUSE® Tablets.
-
January 2011
Sigmapharm files an Abbreviated New Drug Application (ANDA No. 202819).
